NON-SMALL CELL LUNG CANCER (NSCLC)

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if Rina-S can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effects …

This early-phase study tests an experimental drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with…

This study compares a new drug called pumitamig to the standard treatment durvalumab for people with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The goal is to see if pumi…

This study is for people with advanced stage IV non-small cell lung cancer that has spread. It compares standard maintenance therapy (like chemo or immunotherapy) alone versus adding local ablative treatment (surgery or radiation) to the remaining tumor and metastases. The goal i…

This study tests whether the drug taletrectinib can prevent lung cancer from returning in people with a specific genetic marker (ROS1 fusion) after their tumor has been surgically removed. About 180 adults with stage IB to IIIA non-small cell lung cancer will receive either talet…

This early-stage study tests gilteritinib, a drug already used for a type of leukemia, in people with ALK-positive non-small cell lung cancer whose cancer has stopped responding to standard ALK inhibitors. The main goal is to check the drug's safety and find the right dose. About…

This early-stage study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…

This early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 1,300 participants …

This study tests a new drug called RMC-6236 in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 754 people will take part, and the drug is…

This early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancers that have not responded to other treatments. The main goals are to check safety and find the right dose. About 240 adults will take part, and researchers will also …

This study tests a special dye that makes lung cancer cells glow during surgery. About 35 adults with early-stage lung cancer will receive the dye before their operation. The goal is to help surgeons find tumors that are hard to see with the naked eye, which may lead to more comp…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The main goal is to see how RAD301 moves through the body and how much radiation reaches orga…